Influenza Vaccination, ACEI and ARB in the Evolution of SARS-Covid19 Infection

  • End date
    Aug 31, 2023
  • participants needed
  • sponsor
    Consorci Sanitari de Terrassa
Updated on 4 March 2022
ace inhibitor


Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares hemagglutinin as a transmission mechanism and acts on the ACE2 enzyme during infection.

The aim is to evaluate whether the admitted patients who are previously vaccinated or those who were already receiving treatment show a better evolution.


The number of patients admitted at the hospital, their comorbidity (Charlson index), the number of previous treatments, the length of admission, the need or not of the Intensive Care Unit (ICU) and their final status (survivors or non survivors) would be studied.

If patients that previously received the influenza vaccine or treated with ACEI or ARB showed a better evolution, it would be proposed to extend vaccination and the inclusion of ACE inhibidors and ARB in the treatment of infection.

Condition COVID19, Influenza Vaccination, ACE Inhibitors, ARB
Treatment ACE inhibitor, ARB
Clinical Study IdentifierNCT04367883
SponsorConsorci Sanitari de Terrassa
Last Modified on4 March 2022


Yes No Not Sure

Inclusion Criteria

Hospital Admissions at the Hospital of Terrassa from March 1, 2020 for any cause

Exclusion Criteria

For comparison of percentage of Influenza vaccination, ACEI and ARB vs general population, patients from outsite the reference area of the Terrassa Health Consortium would be excluded
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note